key: cord-0835041-0ewgufl3
authors: Yamamoto, Jennifer M.; Donovan, Lois E.; Feig, Denice S.; Berger, Howard
title: Temporary Alternative Screening Strategy for Gestational Diabetes Screening During the COVID-19 Pandemic – The need for a middle ground
date: 2021-08-27
journal: Can J Diabetes
DOI: 10.1016/j.jcjd.2021.08.008
sha: 1ab94a9710369c1c537d2c04cbaf63d14bc28f0d
doc_id: 835041
cord_uid: 0ewgufl3

nan

The COVID-19 pandemic continues to have a significant impact on Canadians, including pregnant women and diabetes in pregnancy care teams. The "Temporary Alternative Screening Strategy for Gestational Diabetes Screening During the COVID-19 Pandemic" recommendations were developed early on in the pandemic, when the degree of impact that the COVID-19 pandemic would have on Canadians was largely unknown [1] . An alternative screening strategy was recommended if the "pandemic caused severe disruptions to laboratory testing and treatment, and/or patient refusal". However, as the pandemic has progressed there has been a wide-range and varying incidence of COVID-19 across Canada, diverse effects on healthcare systems, and differences in the ability of various healthcare infrastructures to adapt. The dichotomy of the current gestational diabetes (GDM) screening criteria does not address the diversity of cases and its effects on the healthcare system across Canada. While COVID-19 cases in Canada have largely declined with public health measures and vaccinations, given the increasing COVID-19 variants and the continued uncertainty of the pandemic, in this perspective, we summarize the COVID-19 screening criteria and propose a middle ground screening pathway for GDM during COVID-19 surges or other situations that might arise and lead to variable disruptions to healthcare delivery.

We continue to highlight the importance of screening for overt diabetes in high-risk women in early pregnancy. As per the 2018 Diabetes Canada Clinical Practice Guidelines, this can be done with a hemoglobin A1c (A1c) or fasting plasma glucose if an A1c is unreliable [2] .

The COVID-19 pandemic has affected different regions at different times throughout the past year. Given this substantial variability, we have proposed an additional "middle ground" screening criterion ( Figure 1 ). The choice of screening procedures should be centre-based depending on each centre's clinical capacity, capacity for adhering to safety measures, and the burden of COVID-19 in the community. In addition to the screening recommendations below, we suggest glucose testing at any time if there is a high clinical suspicion of diabetes.

Option 1 assumes that there are minimal disruptions to testing for and treatment of GDM. Given the lower sensitivity of the other proposed options, the current Diabetes Canada Clinical Practice Guidelines recommendations should be followed unless disruptions affect clinical care and/or laboratory testing capacity for which a change in care delivery is required [2] .

Option 2 assumes that there are moderate disruptions to the testing for and treatment of GDM ( Figure 1 ). Moderate disruptions are defined as anything in between minimal and severe disruptions. This change suggests screening only high-risk women. High-risk is defined as having at least one of the following risk factors:

1) Previous diagnosis of GDM 2) Pre-pregnancy or early pregnancy Body Mass Index (BMI)30 kg/m 2 3) Maternal age 40 years 4) From a high-risk group (African, Arab, Asian, Hispanic, Indigenous, or South Asian)

In this scenario, we suggest screening women with at least one of the risk factors defined above with a non-fasting 50g glucose challenge using the same existing glucose thresholds recommended in the Diabetes Canada 2018 guideline; i.e. women with a 1-hour plasma glucose of 11.1 mmol/L are assumed to have a diagnosis of GDM and women with a 1-hour plasma glucose of 7.8-11.0 mmol/L should have a 75g oral glucose tolerance test (OGTT) [2] . The inclusion of high-risk factors defined above were chosen based on the strongest association with gestational diabetes and in the context of our Canadian population [3] [4] [5] . Based on European data, it can be anticipated that this strategy could result in over 29% of women having these risk factors and thus requiring screening [6] . This strategy could hypothetically miss almost half of women with GDM assuming universal testing with a 75g OGTT and the use of the International Association of Diabetes and Pregnancy Study Group diagnostic criteria (World Health Organization 2013) [6] . The actual performance of this strategy in our diverse Canadian population and without a universal confirmatory OGTT is difficult to accurately predict.

In healthcare and laboratory systems that are able, we suggest consideration of elimination of the 2-hour blood draw on the 75g OGTT. The correlation between the 1-hour and 2-hour 75g OGTT results in pregnancy is strong (0.68 p<0.001) so few women with GDM would be missed by doing a 75g OGTT that only collects glucose samples fasting and 1 hour post 75g glucose load [7] . This reduces maternal exposure time in the laboratory. In addition, this decreases the laboratory resource utilization.

Option 3 assumes severe disruptions to laboratory testing and treatment, and/or patient refusal. Severe disruptions would encompass the most extreme interruption to healthcare delivery such as those seen at the height of the pandemic for example, the cessation of dynamic glucose testing or redeployment of a large number of staff. This option is identical to the COVID-19 "alternative screening strategy" guidelines and suggest that: -All pregnant women without pre-existing diabetes will be screened with A1c & nonfasting, random plasma glucose -Women with an A1c of < 5.7% and a random plasma glucose < 11.1 mmol/L require no further testing or treatment. -Those with an A1c of 5.7% or a random plasma glucose of 11.1 mmol/L are identified as having GDM and should be referred to the interprofessional diabetes and pregnancy healthcare team.

We again highlight that option 3 will miss many women with GDM given its very low sensitivity (sensitivity=26% and specificity=96% using an HbA1c cut off of 5.7%) [8, 9] . However, it may still be required for systems that lack the laboratory capacity and resources to perform dynamic glucose testing in a safe manner. As well, it may be an option for women who refuse other testing because of the concern for exposure to COVID-19 during testing. 

Temporary Alternative Screening Strategy for Gestational Diabetes Screening During the COVID-19 Pandemic. A Joint Consensus Statement from the Diabetes Canada Clinical Practice Guidelines Steering Committee* and the Society of Obstetricians and Gynecologists of Canada

Diabetes Canada Clinical Practice Guidelines Expert Committee

Risk factors for gestational diabetes mellitus: implications for the application of screening guidelines

Impact of diabetes on maternal-fetal outcomes in Manitoba: Relationship with ethnic and environmental factors

BMI and risk of gestational diabetes among women of South Asian and Chinese ethnicity: a population-based study

Risk factor screening for gestational diabetes mellitus based on the 2013 WHO criteria

Hyperglycemia and adverse pregnancy outcomes

Approaches to screening for hyperglycaemia in pregnant women during and after the COVID-19 pandemic

Testing for gestational diabetes during the COVID-19 pandemic. An evaluation of proposed protocols for the United Kingdom, Canada and Australia